VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Comparison

Salmonella Typhimurium gyrA/cpxA/rpoB mutant vaccine Salmonella Typhimurium ompD/nmpC mutant vaccine
Vaccine Information Vaccine Information
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Pigs
  • cpxA gene engineering:
    • Type: Gene mutation
    • Description: This gyrA/cpxA/rpoB mutant is from Salmonella Typhimurium (Roesler et al., 2004).
    • Detailed Gene Information: Click Here.
  • gyrA gene engineering:
    • Type: Gene mutation
    • Description: This gyrA/cpxA/rpoB mutant is from Salmonella Typhimurium (Roesler et al., 2004).
    • Detailed Gene Information: Click Here.
  • rpoB gene engineering:
    • Type: Gene mutation
    • Description: This gyrA/cpxA/rpoB mutant is from Salmonella Typhimurium (Roesler et al., 2004).
    • Detailed Gene Information: Click Here.
  • Immunization Route: Oral immunization
  • Vaccine Ontology ID: VO_0002900
  • Type: Live, attenuated vaccine
  • Status: Research
  • Host Species as Laboratory Animal Model: Pig
  • NmpC gene engineering:
    • Type: Gene mutation
    • Description: This ompD/nmpC mutant is from Salmonella Typhimurium (Selke et al., 2007).
    • Detailed Gene Information: Click Here.
  • Immunization Route: Oral immunization
Host Response Host Response

Pig Response

  • Persistence: A gyrA/cpxA/rpoB mutant was attenuated in pigs (Roesler et al., 2004).
  • Efficacy: A gyrA/cpxA/rpoB mutant protected pigs against challenge with wild type Salmonella Typhimurium (Roesler et al., 2004).
  • Host IgM response
    • Description: A significant discrimination between vaccinated and non-vaccinated pigs was observed when IgM was measured after challenge, but here, the non-immunized animals had an elevated humoral antibody response after challenge with wild type Salmonella. The first significant difference was seen on day 35 after vaccination (Roesler et al., 2004).
    • Detailed Gene Information: Click Here.

Pig Response

  • Persistence: An ompD/nmpc mutant is attenuated in pigs (Selke et al., 2007).
  • Efficacy: In a pig infection experiment including two oral immunizations with SalmoporcDeltaompD (OmpD, nmpC) and challenge with a multiresistant S. enterica serovar Typhimurium DT104 clinical isolate, we confirmed the protective efficacy of SalmoporcDeltaompD (Selke et al., 2007).
References References
Roesler et al., 2004: Roesler U, Marg H, Schröder I, Mauer S, Arnold T, Lehmann J, Truyen U, Hensel A. Oral vaccination of pigs with an invasive gyrA-cpxA-rpoB Salmonella Typhimurium mutant. Vaccine. 2004; 23(5); 595-603. [PubMed: 15542179].
Selke et al., 2007: Selke M, Meens J, Springer S, Frank R, Gerlach GF. Immunization of pigs to prevent disease in humans: construction and protective efficacy of a Salmonella enterica serovar Typhimurium live negative-marker vaccine. Infection and immunity. 2007; 75(5); 2476-2483. [PubMed: 17296750].